Evercore ISI lowered the firm’s price target on Baxter (BAX) to $45 from $46 and keeps an Outperform rating on the shares. After earnings, the analyst thinks clarifying the stranded cost impact should instill confidence in Baxter’s ability to hit its 16.5% operating margin target, adding that the firm thinks “there is some conservatism being backed into the 4-5% FY25 outlook.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter price target lowered to $36 from $40 at Wells Fargo
- Baxter International Reports Resilient Q3 2024 Performance
- Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
- Baxter sees Q4 adjusted EPS 77c-81c, consensus 84c
- Baxter cuts FY24 adjusted EPS view to $2.90-$2.94 from $2.93-$3.01